Salarius Pharmaceuticals, Inc. (SLRX)
SLRX moved a median of 0.00% 30 minutes after news, and -1.56% by the close. How SLRX actually reacts to news — the realized, point-in-time move the market made, measured across 137 labeled events over the last three years with zero look-ahead.
SLRX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 132 |
| 30-min | 0.00% | 42% | 135 |
| 60-min | 0.00% | 46% | 133 |
| to close | -1.56% | 33% | 133 |
| Middle 50% of SLRX reactions | -3.37% to +1.26% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 137 |
Half of all Salarius Pharmaceuticals, Inc. news events land between -3.37% and +1.26% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SLRX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SLRX's baseline. Nothing else.
Recent SLRX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form DEF 14A Salarius Pharmaceuticals For: Feb 24 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form 8-K Salarius Pharmaceuticals For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics | Press release | GlobeNewswire | +1.97% | +18.98% | |
| Form 8-K Salarius Pharmaceuticals For: Dec 31 | SEC filing · Form 8-K | SEC EDGAR | +0.99% | -3.52% | |
| Form PRE 14A Salarius Pharmaceuticals For: Feb 24 | SEC filing · Form PRE | SEC EDGAR | +0.00% | +1.16% | |
| Form 8-K Salarius Pharmaceuticals For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | -3.38% | -6.08% | |
| Form DEFA14A Salarius Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | -3.38% | -6.08% | |
| Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting | Press release | GlobeNewswire | +0.00% | -1.30% | |
| Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform | Press release | GlobeNewswire | +2.34% | +4.86% | |
| Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study | Press release | GlobeNewswire | -2.64% | -7.41% | |
| Form 8-K Salarius Pharmaceuticals For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | -5.13% | |
| Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” | Press release | GlobeNewswire | +11.64% | +6.97% | |
| Form 8-K Salarius Pharmaceuticals For: Nov 17 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | -6.97% | |
| Form 10-Q Salarius Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.44% | -18.66% | |
| Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger | Press release | GlobeNewswire | -2.92% | — | |
| Strong Earnings and Biotech Resilience Define the Midweek Momentum | Press release | GlobeNewswire | -9.79% | -9.09% | |
| Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering | Press release | PR Newswire | -10.44% | -14.78% | |
| Form DEF 14A Salarius Pharmaceuticals For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | -0.29% | -4.50% | |
| Form DEFA14A Salarius Pharmaceuticals | SEC filing · Form DEFA14A | SEC EDGAR | +0.93% | -4.22% | |
| Form 8-K Salarius Pharmaceuticals For: Oct 21 | SEC filing · Form 8-K | SEC EDGAR | — | -5.03% | |
| Form S-1/A Salarius Pharmaceuticals | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -5.97% | |
| Form 8-K Salarius Pharmaceuticals For: Oct 10 | SEC filing · Form 8-K | SEC EDGAR | -0.25% | +5.43% | |
| Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements | Press release | GlobeNewswire | +0.50% | -1.25% | |
| Form 8-K Salarius Pharmaceuticals For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | +13.00% | |
| Form S-1/A Salarius Pharmaceuticals | SEC filing · Form S-1 | SEC EDGAR | +0.24% | -2.85% | |
| Form 8-K Salarius Pharmaceuticals For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +2.54% | +5.07% | |
| Form 8-K Salarius Pharmaceuticals For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | +0.22% | |
| Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | GlobeNewswire | +0.65% | +0.22% | |
| Form 8-K Salarius Pharmaceuticals For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | -0.35% | -0.70% | |
| Form 8-K Salarius Pharmaceuticals For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | -0.91% | +4.02% | |
| Form 8-K/A Salarius Pharmaceuticals For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | -0.91% | +4.02% | |
| Form 8-K Salarius Pharmaceuticals For: Aug 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.72% | |
| Form 8-K Salarius Pharmaceuticals For: Aug 17 | SEC filing · Form 8-K | SEC EDGAR | +1.33% | +4.38% | |
| Form 8-K Salarius Pharmaceuticals For: Aug 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +5.31% | |
| Form S-3 Salarius Pharmaceuticals | SEC filing · Form S-3 | SEC EDGAR | +1.33% | +4.38% | |
| Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split | Press release | GlobeNewswire | +2.11% | -3.68% | |
| Form 10-Q Salarius Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.06% | -1.26% | |
| Form S-1/A Salarius Pharmaceuticals | SEC filing · Form S-1 | SEC EDGAR | +0.68% | -5.91% | |
| Form 8-K Salarius Pharmaceuticals For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -0.03% | -5.73% | |
| Form S-1/A Salarius Pharmaceuticals | SEC filing · Form S-1 | SEC EDGAR | +0.00% | -15.92% | |
| Form 8-K Salarius Pharmaceuticals For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | -4.91% | -14.45% | |
| Form 8-K Salarius Pharmaceuticals For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | +15.69% | — | |
| Form 8-K Salarius Pharmaceuticals For: Jul 18 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | +11.86% | |
| Form 8-K Salarius Pharmaceuticals For: Jul 10 | SEC filing · Form 8-K | SEC EDGAR | -5.59% | -4.51% | |
| Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard | Press release | GlobeNewswire | -5.59% | -4.51% | |
| Salarius Pharmaceuticals’ Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies | Press release | GlobeNewswire | +1.95% | -11.05% | |
| Form 8-K Salarius Pharmaceuticals For: Jul 08 | SEC filing · Form 8-K | SEC EDGAR | -3.69% | -2.47% | |
| Form 8-K Salarius Pharmaceuticals For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | -15.20% | -16.00% | |
| Form S-1/A Salarius Pharmaceuticals | SEC filing · Form S-1 | SEC EDGAR | -15.20% | -16.00% | |
| Form 8-K Salarius Pharmaceuticals For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.03% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SLRX section they belong to.
Where else SLRX is measured.
SLRX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Salarius Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled SLRX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 137 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of SLRX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SLRX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.